Meet the 2022 Endocrine Society Laureates: Ken K.Y. Ho, MD, FRACP, FRCP, FAHMS

Ho_Laureate2022

Ken K.Y. Ho, MD, FRACP, FRCP, FAHMS 

Outstanding Scholarly Physician Award

Ken K.Y. Ho, MD, FRACP, FRCP, FAHMS, is emeritus professor at the Garvan Institute, University of New South Wales, and honorary consultant endocrinologist, St. Vincent’s Hospital in Sydney, Australia. 

As a globally recognized pituitary medicine expert and a leader in academic clinical endocrinology, he’s developed therapeutic guidelines and advocated for regulatory agency decisions geared toward improving patient outcomes. He established a gold-standard diagnostic test for growth hormone (GH) deficiency and developed standards for use of GH replacement therapy in adults. 

He’s published over 250 peer-reviewed studies that directly impact clinical practice and is currently an associate editor for the Journal of the Endocrine Society and a member of the Society’s Nominating Committee. 

How has the Endocrine Society supported your professional development/career journey?

The Endocrine Society has been integral to my career development in providing a culture of academic excellence for clinicians and a governance structure of engagement and inclusion.

As a Laureate Award recipient, do you have any advice for those just beginning their careers?

Follow your passion guided by the signposts for learning and for achieving clinical and scholarly excellence from a mentor and your Society.

You may also like

  • Holly A. Ingraham, PhD, Receives FASEB Excellence in Science Lifetime Achievement Award

    Endocrine Society member Holly A. Ingraham, PhD, is the recipient of the FASEB Excellence in Science Lifetime Achievement Award. On April 8, the organization announced the winners of its 2024 Excellence in Science Awards, which highlight outstanding achievements by women in biological sciences who demonstrate not only excellence and innovation in their research fields, but…

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

Find more in